Morgan Stanley Maintains "Underweight" Rating for Bristol-Myers Squibb (NYSE: BMY)

Core Viewpoint - Morgan Stanley maintains an "Underweight" rating for Bristol-Myers Squibb, advising investors to hold the stock, which is priced around $61.46 [1][6] Company Strategy - Bristol-Myers Squibb's "focused execution" strategy in 2025 has positively influenced its outlook for 2026, emphasizing newer brands and late-stage pipeline catalysts while managing costs to counteract loss-of-exclusivity challenges [2] Financial Performance - In Q4 2025, Bristol-Myers Squibb reported a strong performance with a growth portfolio increase of 15% year-over-year, which nearly offset a $4 billion revenue decline from its legacy portfolio [3][6] - The total revenue for Q4 remained stable at approximately $12.5 billion, with a stock price increase of 3.44% to $61.57 [4][6] Market Data - The stock has fluctuated between $59.77 and $61.86, with a market capitalization of about $125.34 billion, and has seen a 52-week high of $63.33 and a low of $42.52 [4][5] - Trading volume stands at 5.4 million shares, indicating active market participation despite the "Underweight" rating [5]